Generated by AI
Alkermes plc is a global biopharmaceutical company focused on developing and commercializing medicines for complex neurological and psychiatric conditions. Its current portfolio addresses opioid dependence, alcohol dependence, schizophrenia, bipolar I disorder, and narcolepsy, serving patients and healthcare providers primarily in the United States and international markets. The company combines proprietary drug development with specialized delivery technologies designed to support treatment continuity and clinical use. Its products include long-acting injectable therapies and oral medicines, giving healthcare professionals options across different treatment settings and patient needs. Alkermes plc also maintains clinical and preclinical programs centered on neurological disorders, reinforcing its role in neuroscience-focused pharmaceutical research. Through its commercial medicines, research capabilities, and presence in behavioral health markets, the company contributes to the development and availability of treatments for conditions that can require sustained management and coordinated care. Headquartered in Ireland, Alkermes plc operates across research, manufacturing, regulatory, and commercial functions within the biopharmaceutical industry.
WebsiteConnaught House
Dublin, D04 C5Y6
Ireland
The latest articles about ALKS.
Summary of Sep 21's posts. Generated by AI.
Summary of Apr 27's posts. Generated by AI.
Summary of Feb 14's posts. Generated by AI.
Summary of Mar 31's posts. Generated by AI.
Investors talking about ALKS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.